A security researcher claims to have discovered a way to hide extra information inside emoji.

These projections underscore the market's confidence in Sarepta's ability to capitalize on its current momentum. Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth ...

Elevidys, Sarepta's gene therapy for DMD, has emerged as the company's primary growth engine. Following its label expansion to include patients aged 6 years and older, the therapy has seen ...

In a display of law enforcement diligence, the Happy Valley Police Department has successfully retrieved a stolen bicycle valued at $5,000 belonging to a Marine Corps veteran from Vancouver ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Looking ahead, CRISPR Therapeutics faces both opportunities and challenges. The company's diverse pipeline, including programs in oncology, autoimmune diseases, and in vivo gene editing, offers ...

While Beam's technology shows promise, the company faces significant competition in the gene editing space, particularly in SCD treatment. Analysts note that Beam is likely to be the fourth ...

While Beam's technology shows promise, the company faces significant competition in the gene editing space, particularly in SCD treatment. Analysts note that Beam is likely to be the fourth entrant in ...